Normalized data and raw data generated during the current study are available in Gene Expression Omnibus (GEO) with accession number 136371 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE136371>).

Introduction {#sec001}
============

Cystic fibrosis (CF; OMIM 219700) is an autosomal recessive inherited disease that affects approximately 1/3000 newborns \[[@pone.0231285.ref001]\]. It results from impairment of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a chloride channel expressed at the apical membrane of various epithelial cells. The defective protein results in thick, sticky and obstructive mucus in multiple organs of the respiratory, digestive and reproductive systems \[[@pone.0231285.ref001],[@pone.0231285.ref002]\]. The mutant CFTR protein is also responsible for an altered innate and adaptive immune function.

Lung disease is the main cause of morbidity and mortality in cystic fibrosis \[[@pone.0231285.ref002]\]. CF patients present chronic infections and abnormal inflammation of the lungs that lead to progressive airway destruction. The rate of lung function deterioration is variable among patients and associated with the development of comorbidities and chronic infections \[[@pone.0231285.ref001],[@pone.0231285.ref002]\].

CF-related diabetes (CFRD) is a common comorbidity of CF \[[@pone.0231285.ref003]\]. It affects about 20% of adolescents and 40% to 50% of adults, and is associated with more frequent pulmonary exacerbations, accelerated pulmonary function decline and higher mortality. CFRD is characterized by a reduced and delayed insulin response. The beta-cell dysfunction is evident before the onset of diabetes and is already associated with a pulmonary function decline \[[@pone.0231285.ref003]\]. The exact causes of CFRD are not totally elucidated, nor is explained the association between diabetes and accelerated lung function loss. Mutant cftr-/- newborn zebrafishes have fewer beta cells than the wildtype ones, which suggests that the CFTR protein is important for pancreas development \[[@pone.0231285.ref004]\]. In addition, CFTR seems to be critical for insulin exocytosis, which implies that CF patients have an intrinsic pancreatic islet dysfunction \[[@pone.0231285.ref005]\]. Finally, the continuous infiltration of immune cells into the pancreas may contribute to the progressive destruction of the islets \[[@pone.0231285.ref006]\].

The defective CFTR protein and subsequent insufficient mucociliary clearance predispose CF patients to acute and, ultimately, chronic lung infections with opportunistic pathogens \[[@pone.0231285.ref007]\]. Chronic *P*. *aeruginosa* infection is found in approximately 40% of adult CF patients and is also associated with a drastic decrease of lung function \[[@pone.0231285.ref007]\].

Previous genetic studies showed that the clinical variability of CF patients depends not only on the type of mutations in the *CFTR* gene, but also on modifier genes, other genes that modulate the patient phenotype \[[@pone.0231285.ref001]\]. Much current research focuses on finding CF modifier genes to develop new therapies \[[@pone.0231285.ref001]\].

In the present study, we analyzed the transcriptome to identify genes and pathways that (i) contribute to the pathogenesis of cystic fibrosis and (ii) modulate the associated comorbidities. Knockout mice models have limitations because they do not develop spontaneous diabetes, nor do they present lung disease \[[@pone.0231285.ref008]\]; on the other hand, human pancreas and airway tissues are not easily accessible for studies. Herein, we used whole blood samples from CF patients as a surrogate tissue. Of interest, we found that lung function, body mass index (BMI), the presence of diabetes, and chronic *P*. *aeruginosa* infection correlated with modules of co-expressed genes.

Materials and methods {#sec002}
=====================

Study population {#sec003}
----------------

The study population included ≥ 18-year old subjects from the MethylCF cohort: 33 cystic fibrosis patients and 16 healthy controls \[[@pone.0231285.ref009],[@pone.0231285.ref010]\]. A replication set of subjects from the same cohort was used for real-time PCR validation (20 CF patients and 8 healthy controls). The two sets were similar with respect to the age and male-to-female ratio. Demographic and clinical features are reported (**[Table 1](#pone.0231285.t001){ref-type="table"}**). CF patients carried the homozygous p.Phe508del mutation. The presence of diabetes was determined on the basis of an abnormal oral glucose-tolerance test. CF patients were classified as chronically infected by P. *aeruginosa*, methicillin-resistant S. *aureus* and/or A. *fumigatus*, whenever they had three consecutive positive sputum cultures after antibiotic treatment. The study was approved by the "Comité de Protection des Personnes Sud Méditerranée III" Institutional Review Board (2013.02.01bis) and is registered at clinical.gov under reference \#NCT02884. Informed written consent was obtained from all participants.

10.1371/journal.pone.0231285.t001

###### Demographic and relevant clinical features of the MethylCF cohort.

![](pone.0231285.t001){#pone.0231285.t001g}

                                                             Discovery set   Replication set              
  ---------------------------------------------------------- --------------- ----------------- ---------- -------------
                                                             Controls        CF patients       Controls   CF patients
                                                             (n = 16)        (n = 33)          (n = 8)    (n = 20)
  Age, years[†](#t001fn004){ref-type="table-fn"}             28              28 (10)           31         25 (8)
  Sex, M:F                                                   10:6            23:10             3:5        10:10
  BMI, kg/m^2^[†](#t001fn004){ref-type="table-fn"}                           21 (4)                       21 (4)
  Weight, kg[†](#t001fn004){ref-type="table-fn"}                             60 (13)                      60 (12)
  Height, cm[†](#t001fn004){ref-type="table-fn"}                             171 (9)                      168 (11)
  FEV~1~, %[†](#t001fn004){ref-type="table-fn"}                              48 (24)                      48 (24)
  FEV~1~, L[†](#t001fn004){ref-type="table-fn"}                              1.91 (1.1)                   1.70 (0.8)
  FVC, %[†](#t001fn004){ref-type="table-fn"}                                 76 (22)                      68 (28)
  FVC, L[†](#t001fn004){ref-type="table-fn"}                                 3.32 (1.1)                   2.99 (0.6)
  PI, %                                                                      100                          100
  Diabetes, %[\*](#t001fn005){ref-type="table-fn"}                           36                           30
  HbA1c, %[†](#t001fn004){ref-type="table-fn"}                               6.1 (1.1)                    5.4 (na)
  Atopy, %                                                                   18                           45
  *P*. *aeruginosa*, %[§](#t001fn006){ref-type="table-fn"}                   94                           95
  *MRSA*, %[§](#t001fn006){ref-type="table-fn"}                              36                           15
  *A*. *fumigatus*, %                                                        21                           25
  Azythromycin, %                                                            91                           100
  Aztreonam, %                                                               12                           25
  Colistin, %                                                                39                           50
  Tobramycin, %                                                              55                           50
  Corticosteroid, %                                                          33                           45

BMI, body mass index; CF, cystic fibrosis; FEV~1~, forced expiratory volume in 1 second

FVC, forced vital capacity; HbA1c, glycated hemoglobin fraction; PI, pancreatic insufficiency

MRSA, Methicillin-resistant *Staphyloccocus aureus*.

† Median values (interquartile range).

\* The presence of diabetes was determined on the basis of an abnormal oral glucose-tolerance test.

§ CF patients were classified as chronically infected by P. *aeruginosa*, MSRA and/or A. *fumigatus*

whenever they had three consecutive positive sputum cultures after antibiotic treatment.

na, not applicable because only five measurements were available.

RNA sequencing and differential expression analysis {#sec004}
---------------------------------------------------

RNA was extracted from whole blood samples using the PAXgene Blood RNA kit (\#762124, PreAnalytix), according to the manufacturer's recommendations \[[@pone.0231285.ref009]\]. Total RNA sequencing libraries were prepared with the TruSeq Stranded Total RNA kit (Illumina®) and ribosomal RNA was depleted using the Ribo-Zero Gold rRNA removal kit following the manufacturer\'s instructions. Libraries were sequenced in paired-end 75 nucleotides mode with a HiSeq4000 Illumina. The quality of raw sequenced reads was assessed using the FASTQC quality control tool and reads were mapped to the reference human genome build hg19/GRCh37 with Tophat 2 \[[@pone.0231285.ref011]\]. We used HTSeq to obtain the number of reads associated with each gene in the Gencode v26lift37 database (restricted to protein-coding genes, antisense and lincRNAs) \[[@pone.0231285.ref012]\]. The differential expression of the annotated genes was calculated using DESeq \[[@pone.0231285.ref013]\]. Transcripts with a minimum 2-fold change and a Benjamin-Hochberg adjusted p-value (FDR) \< 0.05 were considered as differentially expressed. Normalized data and raw data generated during the current study are available in Gene Expression Omnibus (GEO) with accession number 136371 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE136371>).

Real-time PCR validation {#sec005}
------------------------

Total RNA from whole blood samples were reverse transcribed from 500 ng as previously described \[[@pone.0231285.ref009]\]. Primers were designed using Primer3Plus and Beacon Designer Free Edition online tools, using a Gibbs energy threshold of ΔG ≥ -2.0 for hetero- and homodimers and a GC content \> 40% (**[S1 Table](#pone.0231285.s003){ref-type="supplementary-material"}**). All primers were tested to display an efficiency of amplification of at least 93% (±SD 6%). Amplicons overlapped exon junctions except for CITF22-49E9.3. Real-time PCR reactions were done in duplicate in two independent reverse transcriptions, using SYBR Green I Master mix (Roche Diagnostics) and a LightCycler 480 Instrument. The reverse transcription reaction program consisted of 10 min pre-incubation at 95°C followed by a three step amplification (95°C for 10 s, 60°C for 20 s, 72°C for 10 s). Standard curves were generated by serial dilutions of a control cDNA. Expression levels were expressed as ratios relative to that of the reference gene (*YWHAZ*), using the Pffafl method (with efficiency correction) \[[@pone.0231285.ref014]\]. Differences between groups were analyzed with Wilcoxon test and were considered significant when p-value \< 0.05.

Weighted Gene Correlation Network Analysis {#sec006}
------------------------------------------

To identify modules of co-expressed genes, we implemented Weighted Gene Correlation Network Analysis in the WGCNA R package \[[@pone.0231285.ref015]\]. We used the WGCNA functions to (i) construct a network of coexpressed and highly connected genes, (ii) identify modules of coexpressed genes, and (iii) correlate the gene modules with biological features (continuous or binary phenotypic traits) of the MethylCF cohort. Unless otherwise specified below, we used the default parameters as described by \[[@pone.0231285.ref015]\].

Briefly, we preselected a list of 15077 genes with a FPKM \> 0.1 and log2-transformed the FPKM values (FPKM value +1). Then, we generated a signed adjacency matrix using the biweight midcorrelation and raising it to the power beta = 18 to reduce the noise. The adjacency network exhibited approximate scale-free topology (R^2^ = 0.92). Scale-free topology is obtained when few genes are highly connected to each other (hub genes), whereas the remaining genes are weakly connected. The adjacency matrix was transformed into a topological overlap matrix, an adjacency matrix that considers coexpression information and topological similarity. Modules were generated using the dynamic tree cut and modules with highly correlated module eigengenes (correlation \> 0.75) were merged together. Correlations between the modules of co-expressed genes (eigengenes) and clinical and demographic features of the MethylCF cohort were calculated. Top genes in the modules were visualized with Cytoscape \[[@pone.0231285.ref016]\].

Gene ontology analysis {#sec007}
----------------------

Gene ontology (GO) and KEGG pathways were analyzed with WebGestalt (WEB-based GEne SeT AnaLysis Toolkit; URL: [http://www.webgestalt.org](http://www.webgestalt.org/)) using the Benjamini--Hochberg correction for multiple testing \[[@pone.0231285.ref017]\]. For GO, we retained a false discovery rate of 5%, excluding categories with less than four genes. For KEGG pathway analyses, we used a false discovery rate of either 1% or 5%.

Results {#sec008}
=======

RNA sequencing and biotype distribution {#sec009}
---------------------------------------

Whole blood samples had been collected from CF patients with no ongoing pulmonary exacerbation \[[@pone.0231285.ref009]\]. Total blood cell count and the percentage of different types of leukocytes were within normal range. The median percentages calculated on 19 CF patients were 60% (iqr 14.7%) neutrophils, 26% (iqr 12.0%) lymphocytes, 9% (iqr 3.0%) monocytes, 3% (iqr 2.6%) eosinophils, 1% (iqr 0.5%) basophils. We collected the blood samples in PAXgene tubes that stabilize RNA, preserve all types of circulating cells (leukocytes and platelets) and do not alter the gene expression profile of frozen samples \[[@pone.0231285.ref018]\].

Using RNA-seq, we generated the transcriptome of 49 blood samples from the MethylCF cohort \[[@pone.0231285.ref009],[@pone.0231285.ref010]\]. Eight samples were excluded because ribosomal depletion failed. Hence, the bioinformatic analyses were carried out on 41 samples (27 CF patients and 14 controls). The median total number of reads per sample was 112 million (iqr 17 million). We found that 9324 protein coding genes, 501 antisense transcripts and 493 lincRNA were expressed in blood samples (FPKM \>1). Biotype distribution and expression level of the corresponding transcripts are represented in **[S1 Fig](#pone.0231285.s001){ref-type="supplementary-material"}**.

Differentially expressed genes between CF patients and controls {#sec010}
---------------------------------------------------------------

When we compared gene expression between CF patients and controls, we found 75 differentially expressed (DE) genes (48 genes were over-expressed and 27 genes were under-expressed in CF patients) (Log~2~foldChange ≥ 1 or ≤ -1; FDR \< 0.05) (**[Fig 1](#pone.0231285.g001){ref-type="fig"}**, **[S2 Table](#pone.0231285.s004){ref-type="supplementary-material"}**). Thirteen non-coding RNAs were over-expressed and two non-coding RNAs were under-expressed in CF patients compared to controls (**[S2 Table](#pone.0231285.s004){ref-type="supplementary-material"}**).

![Differentially expressed gene between CF patients and controls.\
The volcano plot represents the Log~2~ transformed fold-changes (x-axis) and the Log~10~ transformed q-values (y-axis). 48 genes were over-expressed (red) and 27 genes were under-expressed (green) in CF blood samples (FDR \< 0.05).](pone.0231285.g001){#pone.0231285.g001}

Gene ontology (GO) analysis showed that DE genes between CF patients and controls were overrepresented among genes important for the response to bacterial infection (FDR p-value = 1.2E-05, 19 genes including *TLR5*, *S100A8*, *S100A12*, *ILR23R)* and leukocyte activation (FDR p-value = 3.4E-04, 11 genes including *IL23R*, *IL4R*, *CDC80*, *TBX21*) (**[S3 Table](#pone.0231285.s005){ref-type="supplementary-material"})**. KEGG analysis highlighted the Th17 lymphocyte activation pathway (FDR p-value = 4.6E-03, 7 genes: *MAPK14*, *IL23R*, *TBX21*, *HLA-DOA*, *IL2RB*, *IL4R*, *RORC)*.

Validation of RNA-seq data with real-time PCR {#sec011}
---------------------------------------------

To validate the RNA-seq data, we assessed the expression levels of three DE genes (*TLR5*, *CLEC4D*, and *ALPL*) and one DE lincRNA (CITF22-49E9.3) using real-time PCR in the same set of blood samples (n = 49) as a technical validation, and in a replication set (n = 28) as a biological validation (**[Table 2](#pone.0231285.t002){ref-type="table"}**). We selected protein-coding and non-coding transcripts among the top DE genes with a relevant biological function and a range of expression levels (from 5 to 56 FPKM). *TLR5*, *CLEC4D*, *ALPL* and CITF22-49E9.3 were differentially expressed between CF patients and controls of the discovery set, and thus technically validated (p-value \< 0.01). *TLR5*, *CLEC4D*, and *ALPL* were biologically validated since their expression levels differed between CF patients and controls of the replicative set (p-value \< 0.05). CITF22-49E9.3 failed to be biologically validated (p-value = 0.18), but the direction was the same as in RNA-seq (over-expression in CF). For all loci, the direction of differential expression was identical and fold-changes were similar between RNA-seq and real-time PCR data, showing a total concordance between the two techniques (**[Table 2](#pone.0231285.t002){ref-type="table"}**).

10.1371/journal.pone.0231285.t002

###### Validation of RNA-seq data by real time-PCR.
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                      *RNA-seq---*Discovery set   *real time-PCR*---Discovery set   *real time-PCR---*Replication set                                                                    
  ------------------- --------------------------- --------------------------------- ----------------------------------- --------- -------- ------- ------ --------- ------ ------ ------ ---------
                      Med CF                      Med C                             Med CF                              Med C     Med CF   Med C                                         
  **TLR5**            13.87                       4.69                              2.96                                3.9E-05   2.59     1.15    2.26   6.6E-05   2.72   1.39   1.96   3.9E-03
  **CLEC4D**          14.70                       8.73                              1.68                                3.5E-05   5.72     2.60    2.20   2.6E-06   4.68   2.61   1.79   1.6E-02
  **ALPL**            49.21                       19.32                             2.55                                7.9E-04   2.34     0.84    2.80   7.3E-03   2.88   0.91   3.18   2.1E-03
  **CITF22-49E9.3**   9.35                        5.38                              1.74                                6.1E-05   3.37     2.09    1.61   1.5E-06   3.15   2.20   1.43   1.8E-01

FPKM: Fragments Per Kilobase of transcript per Million mapped reads, Med: median, CF: Cystic Fibrosis, C: Control, FC: fold-change (CF/C).

† CF vs C, Wilcoxon test.

Weighted Gene Correlation Network Analysis {#sec012}
------------------------------------------

Next, to find additional genes important for CF pathogenesis and the associated comorbidities, we implemented Weighted Gene Correlation Network Analysis (WGCNA) \[[@pone.0231285.ref015]\]. Using RNA-seq datasets from 27 CF patients of the MethylCF cohort, we found 28 modules of co-expressed genes (**[S4 Table](#pone.0231285.s006){ref-type="supplementary-material"}**). The number of genes in each module ranged from 35 to 2839. A majority of modules were enriched with genes that belong to biological pathways (Notch signaling, MAPK signaling, platelet activation, B cell receptor, etc), which suggests that the gene modules are biologically meaningful (**[Table 3](#pone.0231285.t003){ref-type="table"}**).

10.1371/journal.pone.0231285.t003

###### Module of coexpressed genes: KEGG analysis.
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                  Size[\*](#t003fn001){ref-type="table-fn"}   KEGG [§](#t003fn002){ref-type="table-fn"}   Pathway                                     N     R      FDR
  --------------- ------------------------------------------- ------------------------------------------- ------------------------------------------- ----- ------ ---------
  Darkgreen       90                                                                                                                                               n.s.
  Red             802                                         hsa04330                                    Notch signaling pathway                     48    6.9    4.3E-04
  Turquoise       2838                                        hsa04666                                    Fc gamma R-mediated phagocytosis            91    6.7    8.0E-10
  Black           679                                         hsa00310                                    Lysine degradation                          59    6.5    4.2E-03
  Tan             243                                         hsa05210                                    Colorectal cancer                           86    7.8    1.8E-02
  White           35                                          hsa04120                                    Ubiquitin mediated proteolysis              137   10.2   6.8E-03
  Orange          66                                          hsa04217                                    Necroptosis                                 162   12.1   1.3E-06
  Royalblue       140                                         hsa04621                                    NOD-like receptor signaling                 168   8.6    1.8E-06
  Darkred         107                                                                                                                                              n.s.
  Greenyellow     320                                         hsa04932                                    Non-alcoholic fatty liver disease           149   7.1    2.5E-06
  Purple          573                                         hsa04144                                    Endocytosis                                 244   3.3    3.2E-04
  LightYellow     143                                         hsa04611                                    Platelet activation                         122   8.2    9.3E-05
  Magenta         595                                                                                                                                              n.s.
  Salmon          235                                                                                                                                              n.s.
  Cyan            173                                         hsa03050                                    Proteasome                                  44    20.4   1.0E-05
  Darkgrey        68                                          hsa05203                                    Viral carcinogenesis                        201   14.2   0.0E+00
  Lightgreen      145                                                                                                                                              n.s.
  Pink            673                                         hsa04010                                    MAPK signaling                              255   2.8    1.0E-03
  Darkturquoise   79                                                                                                                                               n.s.
  Grey60          156                                         hsa01230                                    Biosynthesis of amino acids                 75    8.2    6.7E-03
  Darkorange      59                                                                                                                                               n.s.
  Midnightblue    171                                         hsa04650                                    Natural killer cell mediated cytotoxicity   131   6.3    0.0E+00
  Brown           1484                                        hsa03010                                    Ribosome                                    154   12.2   0.0E+00
  Green           1097                                        hsa03010                                    Ribosome                                    153   6.4    1.6E-12
  Lightcyan       169                                         hsa04662                                    B cell receptor signaling                   71    16.2   7.8E-06
  Blue            1859                                        hsa04660                                    T cell receptor signaling                   101   4.9    2.6E-02
  Yellow          1320                                                                                                                                             n.s.
  Grey            757                                                                                                                                              n.s.

\*Number of genes in the module

§ Top KEGG pathway

N, number of genes in the pathway. R, ratio of enrichment. FDR, false discovery rate

n.s., not significant, p-value \> 0.05 after Benjamini-Hochberg correction

Next, we calculated the correlation between the clinical traits of the patients and the eigengenes of the modules (**[Fig 2](#pone.0231285.g002){ref-type="fig"})**. The eigengene is the first component of a principal component analysis and represents the summary of the gene expression profile of the module \[[@pone.0231285.ref015]\]. Modules of co-expressed genes that correlated with lung function, the presence of diabetes, and a chronic *P*. *aeruginosa* infection were analyzed in more detail.

![WGCNA on blood RNA-seq dataset.\
The heatmap represents the correlation (coefficient and p-value) between eigengene modules and clinical traits. Module sizes are shown in the colored boxes.](pone.0231285.g002){#pone.0231285.g002}

Lung function metrics included forced expiratory volume in 1 second (FEV~1~) and forced vital capacity (FVC) expressed in liters and as a percent predicted based on age, sex and height \[[@pone.0231285.ref019]\]. These clinical measures are used for the follow-up of CF patients and as endpoints to assess whether patients respond to treatments \[[@pone.0231285.ref020]\]. In the MethylCF cohort, lung function and BMI best correlated with the dark turquoise module. For simplicity, only FEV~1~ (%) was represented (**[Fig 2](#pone.0231285.g002){ref-type="fig"}**), however, consistent results were obtained with FVC (%) (r = 0.54 p-value = 4.0E-03). The GO analysis of the dark turquoise module highlighted terms related to cell-cell adhesion and cell adherence junctions (**[Table 4](#pone.0231285.t004){ref-type="table"}**). *FLNA* is a hub gene of this module. It encodes Filamin A, an actin-binding and scaffolding protein that interacts with integrins to regulate leukocyte trafficking (**[Fig 3](#pone.0231285.g003){ref-type="fig"}**) \[[@pone.0231285.ref021]\].

![Network representation of dark turquoise and light yellow modules.\
Top genes and their connections were visualized with Cytoscape \[[@pone.0231285.ref016]\]. Genes of interest were emphasized. For each module the correlated clinical traits and main gene ontology (GO) terms are shown.](pone.0231285.g003){#pone.0231285.g003}

10.1371/journal.pone.0231285.t004

###### GO terms for dark turquoise module correlated with lung function and BMI, and light yellow module correlated with diabetes.
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  Geneset                                                         Description                                                      Number of genes   Ratio of enrichment   FDR
  --------------------------------------------------------------- ---------------------------------------------------------------- ----------------- --------------------- ---------
  **DARKTURQUOISE MODULE**                                                                                                                                                 
  ***BIOLOGICAL PROCESS***                                                                                                                           n.s.                  
  ***CELLULAR COMPONENT***[\*](#t004fn001){ref-type="table-fn"}                                                                                                            
  GO:0030529                                                      intracellular ribonucleoprotein complex                          12                4.4                   7.7E-03
  GO:1990904                                                      ribonucleoprotein complex                                        12                4.4                   7.7E-03
  GO:0005912                                                      adherens junction                                                11                4.3                   1.0E-02
  GO:0061695                                                      transferase complex, transferring phosphorus-containing groups   7                 7.5                   1.0E-02
  GO:0070161                                                      anchoring junction                                               11                4.2                   1.0E-02
  GO:0005730                                                      nucleolus                                                        12                3.8                   1.1E-02
  GO:1990234                                                      transferase complex                                              11                4.0                   1.2E-02
  GO:0044798                                                      nuclear transcription factor complex                             5                 10.1                  1.7E-02
  GO:0005913                                                      cell-cell adherens junction                                      7                 5.9                   2.0E-02
  GO:1902494                                                      catalytic complex                                                14                3.0                   2.0E-02
  ***MOLECULAR FUNCTION***                                                                                                                                                 
  GO:0003723                                                      RNA binding                                                      17                2.8                   3.8E-02
  GO:0044877                                                      macromolecular complex binding                                   15                3.0                   3.8E-02
  GO:0098641                                                      cadherin binding involved in cell-cell adhesion                  7                 6.5                   3.8E-02
  GO:0098632                                                      protein binding involved in cell-cell adhesion                   7                 6.2                   3.8E-02
  GO:0044822                                                      poly(A) RNA binding                                              14                3.1                   3.8E-02
  GO:0098631                                                      protein binding involved in cell adhesion                        7                 6.1                   3.8E-02
  GO:0045296                                                      cadherin binding                                                 7                 6.1                   3.8E-02
  ***KEGG PATHWAY***                                              n.s.                                                                                                     
  **LIGHT YELLOW MODULE**                                                                                                                                                  
  ***BIOLOGICAL PROCESS***[\*](#t004fn001){ref-type="table-fn"}                                                                                                            
  GO:0007596                                                      blood coagulation                                                34                4.2                   6.8E-09
  GO:0042060                                                      wound healing                                                    43                3.4                   6.8E-09
  GO:0050817                                                      coagulation                                                      34                4.1                   6.8E-09
  GO:0007599                                                      hemostasis                                                       34                4.1                   6.8E-09
  GO:0009611                                                      response to wounding                                             44                2.9                   3.4E-07
  GO:0030168                                                      platelet activation                                              20                5.1                   3.5E-06
  GO:0050878                                                      regulation of body fluid levels                                  35                2.9                   1.4E-05
  GO:0002576                                                      platelet degranulation                                           15                6.0                   3.2E-05
  GO:0070527                                                      platelet aggregation                                             10                7.2                   9.3E-04
  GO:0006887                                                      exocytosis                                                       27                2.8                   1.4E-03
  ***CELLULAR COMPONENT***[\*](#t004fn001){ref-type="table-fn"}                                                                                                            
  GO:0031091                                                      platelet alpha granule                                           16                11.4                  4.9E-10
  GO:0031410                                                      cytoplasmic vesicle                                              73                2.3                   6.1E-09
  GO:0097708                                                      intracellular vesicle                                            73                2.3                   6.1E-09
  GO:0044433                                                      cytoplasmic vesicle part                                         49                2.8                   8.4E-09
  GO:0031093                                                      platelet alpha granule lumen                                     12                11.7                  6.4E-08
  GO:0099503                                                      secretory vesicle                                                28                3.3                   8.0E-06
  GO:0034774                                                      secretory granule lumen                                          12                7.6                   8.4E-06
  GO:0030141                                                      secretory granule                                                23                3.5                   3.0E-05
  GO:0005925                                                      focal adhesion                                                   24                3.3                   3.9E-05
  GO:0005924                                                      cell-substrate adherens junction                                 24                3.3                   3.9E-05
  ***MOLECULAR FUNCTION***                                                                                                                           n.s.                  
  ***KEGG PATHWAY***                                                                                                                                                       
  hsa04611                                                        Platelet activation---Homo sapiens (human)                       10                8.2                   9.3E-05

\* Top 10 enriched terms

n.s., not significant after Benjamini-Hochberg correction

Diabetes and glycated hemoglobin (HbA1c) levels correlated with the light yellow module. HbA1c reflects the mean glucose levels over a three-month period. GO analysis of this module revealed terms related to vesicle transport and platelet activation (**[Table 4](#pone.0231285.t004){ref-type="table"}**). Among the hub genes of this network were integrin genes (*ITGB3*, *ITGA2B*, *ITGB5*) (**[Fig 3](#pone.0231285.g003){ref-type="fig"}**).

The presence of diabetes (but not HbA1c levels) also correlated with the cyan module. GO analysis of the genes belonging to this module revealed enrichment for terms related to the proteasome (**[Table 5](#pone.0231285.t005){ref-type="table"}**). Through hierarchical clustering, we identified three groups of CF patients with distinct gene expression signatures and prevalence of diabetes (**[Fig 4](#pone.0231285.g004){ref-type="fig"}**). In the group enriched with diabetic patients (6 out of 9 patients), seven proteasome genes (*PSME4*, *PSMA7*, *PSMB4*, *PSMB6*, *PSMC4*, *PSMD7* and *PSMD8*) and three genes previously associated with common diabetes (*SNX17*, *PARK7/DJ-1* and *ATP5B)* were highly expressed (**[Fig 4](#pone.0231285.g004){ref-type="fig"}**). By contrast, two genes encoding histone methyltransferases (*SMYD3* and *KMT2A*) and one gene encoding a chromatin-remodeling ATPase (*EP400)* were under-expressed in this group of patients.

![Network representation of cyan module.\
Top genes and their connections were visualized with Cytoscape \[[@pone.0231285.ref016]\] (left side). Genes of interest were emphasized. The correlated clinical trait and main gene ontology (GO) term are shown. Hierarchical clustering and heatmap of the cyan genes: purple square, CF patients with diabetes; white square, CF patients without diabetes. C1, C2, C3: cluster 1, 2 and 3, respectively (right side).](pone.0231285.g004){#pone.0231285.g004}

10.1371/journal.pone.0231285.t005

###### GO terms for cyan module correlated with diabetes and magenta module correlated with *P*. *aeruginosa* infection.

![](pone.0231285.t005){#pone.0231285.t005g}

  Geneset                              Description                                          Number of genes   Ratio of enrichment   FDR
  ------------------------------------ ---------------------------------------------------- ----------------- --------------------- ---------
  **CYAN MODULE**                                                                                                                   
  ***BIOLOGICAL PROCESS***                                                                                                          
  GO:0042180                           cellular ketone metabolic process                    9                 8.6                   7.0E-04
  GO:0009308                           amine metabolic process                              7                 12.0                  7.0E-04
  GO:0006520                           cellular amino acid metabolic process                10                5.8                   1.9E-03
  GO:0038061                           NIK/NF-kappaB signaling                              6                 11.5                  2.6E-03
  GO:0007164                           establishment of tissue polarity                     6                 10.6                  3.2E-03
  GO:0001738                           morphogenesis of a polarized epithelium              6                 9.6                   4.7E-03
  GO:0010608                           posttranscriptional regulation of gene expression    10                4.7                   4.9E-03
  ***CELLULAR COMPONENT\****                                                                                                        
  GO:0000502                           proteasome complex                                   6                 25.5                  6.3E-05
  GO:1905369                           endopeptidase complex                                6                 25.5                  6.3E-05
  GO:1902494                           catalytic complex                                    18                4.0                   8.0E-05
  GO:1905368                           peptidase complex                                    6                 18.9                  1.9E-04
  GO:0005844                           polysome                                             4                 25.5                  3.7E-03
  GO:0030529                           intracellular ribonucleoprotein complex              11                4.2                   7.0E-03
  GO:1990904                           ribonucleoprotein complex                            11                4.2                   7.0E-03
  GO:0005839                           proteasome core complex                              3                 40.1                  7.0E-03
  GO:0005838                           proteasome regulatory particle                       3                 38.3                  7.2E-03
  GO:0022624                           proteasome accessory complex                         3                 33.7                  9.6E-03
  ***MOLECULAR FUNCTION***                                                                                                          
  GO:0003723                           RNA binding                                          22                3.7                   2.8E-05
  GO:0044822                           poly(A) RNA binding                                  19                4.3                   2.8E-05
  GO:0004298                           threonine-type endopeptidase activity                3                 37.6                  3.0E-02
  GO:0070003                           threonine-type peptidase activity                    3                 37.6                  3.0E-02
  GO:0035257                           nuclear hormone receptor binding                     5                 10.2                  4.7E-02
  ***KEGG PATHWAY***                                                                                                                
  hsa03050                             Proteasome---Homo sapiens (human)                    6                 29.6                  1.1E-05
  **MAGENTA MODULE**                                                                                                                
  ***BIOLOGICAL PROCESS***^***\****^                                                                                                
  GO:0006778                           porphyrin-containing compound metabolic process      9                 12.9                  1.7E-04
  GO:0016567                           protein ubiquitination                               38                2.6                   3.2E-04
  GO:0030163                           protein catabolic process                            38                2.5                   5.2E-04
  GO:0006779                           porphyrin-containing compound biosynthetic process   7                 15.1                  5.2E-04
  GO:0030218                           erythrocyte differentiation                          12                6.5                   5.5E-04
  GO:0033014                           tetrapyrrole biosynthetic process                    7                 13.4                  7.3E-04
  GO:0046501                           protoporphyrinogen IX metabolic process              5                 25.9                  7.3E-04
  GO:0015669                           gas transport                                        6                 17.3                  7.3E-04
  GO:0034101                           erythrocyte homeostasis                              12                6.0                   7.3E-04
  GO:0032446                           protein modification by small protein conjugation    39                2.3                   7.9E-04
  ***CELLULAR COMPONENT***^***\****^                                                                                                
  GO:0005833                           hemoglobin complex                                   6                 38.3                  3.5E-06
  GO:0030863                           cortical cytoskeleton                                11                9.2                   1.0E-05
  GO:0014731                           spectrin-associated cytoskeleton                     5                 43.9                  1.0E-05
  GO:0005768                           endosome                                             31                2.7                   9.1E-05
  GO:0005773                           vacuole                                              26                2.9                   2.4E-04
  GO:0044448                           cell cortex part                                     11                6.3                   2.4E-04
  GO:0005856                           cytoskeleton                                         54                1.9                   3.4E-04
  GO:0036019                           endolysosome                                         5                 20.6                  3.9E-04
  GO:0031410                           cytoplasmic vesicle                                  48                1.9                   5.1E-04
  GO:0097708                           intracellular vesicle                                48                1.9                   5.1E-04
  ***MOLECULAR FUNCTION***                                                                                                          
  GO:0046983                           protein dimerization activity                        41                2.10                  9.4E-03
  ***KEGG PATHWAY***                                                                                          n.s.                  

Top 10 enriched terms

n.s., not significant after Benjamini-Hochberg correction

Finally, the presence of a chronic *P*. *aeruginosa* infection negatively correlated with the eigengene of the magenta module. GO analysis revealed terms related to heme metabolic process and hemoglobin complex (**[Table 5](#pone.0231285.t005){ref-type="table"}**). The magenta network comprised three hub genes encoding the following proteins: SLC25A39 (Solute Carrier Family 25 member 39), a mitochondrial solute carrier protein, GATA1 (GATA Binding Protein 1), an erythroid transcription factor and CDC34 (Cell Division Cycle 34), a ubiquitin-conjugating enzyme (**[S2 Fig](#pone.0231285.s002){ref-type="supplementary-material"}**).

Discussion {#sec013}
==========

CF patients present a clinical heterogeneity that is not fully explained by the type of mutations in the *CFTR* gene. Previous studies emphasized that other genes modulate the clinical phenotype and account for the development of comorbidities \[[@pone.0231285.ref001]\]. CF modifier genes were extensively searched in genetic studies first and more recently in transcriptomic studies \[[@pone.0231285.ref001]\].

Transcriptomic analyses in airway cell lines and nasal epithelial cell samples showed expression changes in genes involved in cell proliferation, inflammation and immune responses, protein metabolism, and calcium and membrane pathways \[[@pone.0231285.ref022]--[@pone.0231285.ref024]\]. More recently, blood samples from CF patients presenting either severe or mild lung disease were analyzed: genes of the type I interferon response and ribosomal stalk proteins were differentially expressed \[[@pone.0231285.ref025]\]. However, no healthy subjects were compared with CF patients in that study.

Herein, we used RNA-seq to profile blood samples from CF patients and healthy controls. An added value of this cohort is that the clinical data were recorded on the same day biological samples were collected. Importantly, in addition to the differential gene expression analysis, we implemented WGCNA.

DE genes between CF patients and controls were overrepresented among genes important for the leukocyte activation and the response to bacterial infection, which is consistent with the permanent inflammation and chronic infections in CF patients. KEGG analysis highlighted the Th17 lymphocytes activation pathway.

A limitation of the DE gene analysis is that a number of relevant genes do not reach significance after correction for multiple tests, unless large cohorts are assembled. But it is difficult to fulfill this condition in rare disease studies. To overcome this drawback, we set up WGCNA \[[@pone.0231285.ref015]\]. WGCNA detects networks of co-regulated and highly connected genes that belong to biological pathways and reduces the number of variables to be tested, thus decreasing the false discovery rate \[[@pone.0231285.ref015]\]. Using WGCNA, we found that clinical traits of interest in cystic fibrosis correlated with modules of co-expressed genes in blood samples.

Because lung disease is the main cause of mortality and morbidity in CF, first we inspected the dark turquoise module that correlated with the lung function (FEV~1~ and FVC) and BMI. Lung function and BMI are positively correlated in CF and their deterioration is predictive of patient decline and, ultimately, patient death \[[@pone.0231285.ref026]\]. The GO analysis of the dark turquoise module showed terms related to cell-cell adhesion and cell adherence junctions. Interestingly, the same association between lung function and cell adhesion was highlighted by the DNA methylation analysis of CF nasal epithelial cell samples \[[@pone.0231285.ref010]\].

In the present transcriptomic study, *FLNA* is a hub gene of the dark turquoise module. The Filamin A protein is an actin-binding and scaffolding protein that binds to integrins and also interacts with CFTR \[[@pone.0231285.ref027]\]. Of interest, mutations in the *FLNA* gene result in interstitial lung disease, a severe respiratory illness \[[@pone.0231285.ref028]\]. The FLNA protein is required for optimal T cell homing into lymph nodes and inflamed tissues \[[@pone.0231285.ref029]\]. To explain the association between lung function and cell adhesion in cystic fibrosis, we argue that if cell junctions are loosened, the leukocyte trafficking from the blood stream to the airways is facilitated, and the resulting high inflammation reduces lung function.

The decline of lung function is steeper in CF patients with diabetes and the fast decay starts 1--3 years before the appearance of diabetes \[[@pone.0231285.ref003]\]. Peaks of hyperglycemia also occur before the appearance of diabetes \[[@pone.0231285.ref003]\]. To explain the association between diabetes and a more rapid lung function decline, modules that correlated with lung function (dark turquoise) and with diabetes and HbA1c levels (light yellow) should be investigated together. Of interest, some of their respective hub genes encode proteins (FLNA and integrins) that bind one to each other to regulate T lymphocyte and neutrophil trafficking \[[@pone.0231285.ref026],[@pone.0231285.ref030]\]. Also, high glucose modifies the levels of the Flna protein in rat endothelial cells \[[@pone.0231285.ref031]\]. All together, these findings suggest that glucose fluctuations can be the initial event that alter the expression of genes responsible for leukocyte trafficking, increases airway inflammation and, thereby, reduces the lung function in cystic fibrosis.

CF patients with diabetes may present microvascular complications, namely retinopathy and nephropathy \[[@pone.0231285.ref003]\]. Platelets are activated by glucose and their abnormalities are the initial event responsible for microvascular complications in diabetes \[[@pone.0231285.ref032]\]. Genes encoding platelet aggregation proteins were overrepresented in the light yellow module which, therefore, should be analyzed in detail with respect to these comorbidities.

The presence of diabetes but not HbA1c levels correlated with the cyan module. It comprised genes that encode proteins of the 20S and 19S proteasome subunits. A pivotal function of the proteasome is to degrade the oxidized and misfolded proteins that are generated by oxidative stress \[[@pone.0231285.ref033]\]. Through visualization of the most connected genes of this module, we identified *SNX17*, previously associated with glucose-homeostasis in muscle and adipose tissues of type 2 diabetic patients \[[@pone.0231285.ref034]\]. The SNX17 protein activates T cells by regulating T cell receptors and integrin recycling in humans \[[@pone.0231285.ref035]\]. *SNX17* is a hub connected to 12 co-expressed genes, namely *PARK7/DJ-1* encoding a protein deglycase and *ATP5B* encoding the mitochondrial ATP synthase B subunit. In diabetic mice, the expression of the ATP5B protein is high and activated by reactive oxygen species (ROS) \[[@pone.0231285.ref036]\]. Overall, genes of the cyan module encode proteins that are activated by and protect from high levels of ROS.

Adult CF patients are sensitized to chronic opportunistic airway infections. In the blood transcriptome dataset, *P*. *aeruginosa* chronic infection negatively correlated with the magenta module. This correlation should be taken with caution because only two patients were not chronically infected by *P*. *aeruginosa*. Genes of the magenta module encode proteins important for erythrocyte differentiation and homeostasis, and for the hemoglobin complex. *SLC25A39*, a hub in this module, codes for a mitochondrial solute carrier protein. Silencing of the mouse Slc25a39 ortholog affected iron incorporation, essential for bacterial growth \[[@pone.0231285.ref037],[@pone.0231285.ref038]\]. Thus, the magenta module points to the role of iron fixation in *P*. *aeruginosa* infections.

The present study has some limitations. We analyzed gene transcription in blood samples from 33 CF patients and 16 healthy controls. Confirmatory studies should be carried out in independent cohorts. We showed that blood is an informative surrogate tissue to address the contribution of inflammation to CFRD. However, evidence exists that this comorbidity also depends on an intrinsic pancreatic islet dysfunction whose study requires access to pancreas samples. Finally, in the future, patients should be followed longitudinally to correlate the gene signatures with the progression of the disease.

Conclusions {#sec014}
===========

In summary, using blood samples from CF patients, we identified modules of co-expressed genes that belong to relevant biological pathways. Detailed inspection of three modules that correlated with the presence of diabetes and lung function pointed to cell adhesion, leukocyte trafficking and production of ROS as central mechanisms in CFRD and pulmonary function decline. A fourth module that correlated with *P*. *aeruginosa* infection comprised genes important for iron fixation. Of note, we showed that blood is an informative surrogate tissue to address the contribution of inflammation to lung disease and diabetes in CF patients. Finally, we provided evidence that WGCNA is much valuable to analyze--omic datasets in rare genetic diseases as patient cohorts are inevitably small.

Supporting information {#sec015}
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###### Genes and modules.

Rows correspond to genes. A total of 15077 genes with FPKM \> 0.1 in blood samples are listed. Columns list the gene name followed by module membership (kMEi) and corresponding p-values for each module of co-expressed genes. Lists of genes with high module membership can be sorted by selecting decreasing kMEi or increasing p-values. The kMEi is the correlation between the expression of a gene and the module eigengene. It ranges between 0 and 1. A gene is highly connected to other genes of a module when its kMEi approaches 1.
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Response to Reviewer \#1:

This study used transcriptome analysis of blood samples from individuals with CF in an attempt to find novel gene modifiers of CF disease. Using a Weighted Gene Correlation Network Analysis (WGCNA) approach, Lung function, BMI, diabetes presence and chronic P. aeruginosa infection were found to be correlated with modules of co-expressed genes. The study is clear and well presented. I have only a few minor comments which, if addressed, would render the article suitable for publication.

Comments:

1\. Methods p.5-6 (Table 1): It would be informative to have the standard error (+/- SEM) for values in this table, rather than just the mean or median values, in order to better assess the similarity between the two patient sets.

In Table 1 of the revised manuscript, we added the interquartile ranges (IQR).

2\. Methods p.7 line 131: primer efficiency was determined to be 93% - presumably this means at least 93%?

Yes, it does mean at least 93%. Line 123 we added "at least".

3\. Methods p. 7-8 (WGCNA section): this section is not very informative for readers who have not used this method of data analysis, and would benefit from a slight expansion to clarify some of the terms.

Lines 135-152, we have summed up the main steps of WGCNA and slightly expanded the paragraph.

4\. Results p 9-10: When presenting results for GO term enrichment a few of the most enriched groups are mentioned here along with a few of the representative genes. It would be more informative if the p values and number of genes in each group were shown in this section to reduce the necessity for looking at the supplementary table.

Lines 193-197, we added the p-values and the number of genes for GO terms.

5\. Results p 10 (Validation by real time PCR): the validation is well described and the results seem to be sound but the number of DE genes/lincRNAs validated is rather low, given the relative ease and rapidity of this technique. Particularly, given the non-validation of the lincRNA in the replication, I wonder why the authors did not try validating one of the other transcripts.

For real-time PCR validation, we selected 4 genes of interest having high, medium and low levels of expression. The lncRNA had rather low levels of expression in blood and was technically validated by real-time PCR in the discovery set of patients, the same used for RNAseq. In the confirmatory set of patients, although it did not reach significance, the lncRNA had the same direction of differential expression (overexpression in CF patients) and a similar fold-change as in RNAseq.

6\. Results (WGCNA section including tables 3-4 and Figs 2-3): this section necessarily contracts the data in order to focus on a few modules of co-expressed genes that correlate with some CF parameters. However, it would be useful to provide a further clarification about the identity of other undiscussed modules which can be seen in Fig. 2. Table S4 is uninformative in this respect, as it is not easy to find the relevant genes in each module, even using the table legend on page 26. Either explain better how the data can be treated to find these genes, or provide another sheet in table S4 with the columns filtered to identify the important genes of each module.

In the revised manuscript, we have added the KEGG analysis of the 28 modules and provided evidence that gene modules are biologically meaningful. See lines 222-225 and Table 3 showing the KEGG analysis of 28 modules.

In the revised legend of Table S4, we have specified how to identify the most connected genes of a module and we have better explained the kMEi (lines 554-560). We wish to keep Table S4 as a whole, including modules that were not analyzed in details and genes that are below our thresholds. This information can be useful for other studies or people interested in other genes.

7\. Discussion p 16-19. The discussion of the suitability of the blood transcriptome for studying the contribution of DE gene expression in CFRD should be extended. In particular it would be interesting to know what proportions of which cell types were present in the whole blood from which the RNA samples were extracted. Some cytological data from similar blood samples to those used in the study would help in this respect, and would allow a fuller appreciation of the functional significance of the data.

In the result section, we have provided blood cell composition for a subset of CF patients. Blood cell composition was within normal ranges, as expected for CF patients without exacerbation. In addition, we have specified that whole blood samples had been gathered in PAXgene tubes that not only stabilize RNA, but also preserve all types of circulating leukocytes. This is not the case for other blood storage methods that alter the cell proportion in blood samples and also the transcriptomic profile. A bibliographic reference has been provided. See lines 162-169 and reference 18.

We preferred to treat the issue in the result section to avoid expanding the discussion in line with referee 2 comments.

Reviewer \#2: In this manuscript, the authors performed RNA-seq analysis of blood samples obtained from patients affected with cystic fibrosis and healthy controls. They analyzed the data obtained by Weighted Gene Correlation Network Analysis and they found a correlation between lung function, body mass index, the presence of diabetes, and chronic P. aeruginosa infections with four modules of co-expressed genes.

This study is original and overall well written, I found the discussion a little bit lengthy. Figure 3 is too dense.

We thank the reviewer for his comments. The discussion was slightly shortened and a few paragraphs were rephrased. Figure 3 was split into figure 3 and figure 4.

Figure legends are not included in the PDF file.

Figure legends are embedded in the manuscript according to PLOS One guidelines.
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